Skip to main content
Log in

Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience)

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Candidemia is a nosocomial infection mostly found in critically ill patients. Our objectives were to evaluate the change in distribution and resistance profile of Candida spp. isolated from candidemic patients in our intensive care unit over two 5-year periods spanning 15 years and to evaluate the risk factors. Records from the microbiology laboratory were obtained, from January 2004 to December 2008 and from January 2013 to December 2017, retrospectively. Antifungal susceptibility was performed by E-test and evaluated according to EUCAST breakpoints. A total of 210 candidemia cases occurred; 238 Candida spp. were isolated in 197 patients (58.8% male; mean age, 59.2 ± 19.6 years). The most predominant risk factor was central venous catheter use. Species distribution rates were 32%, 28%, 17%, and 11% for C. albicans (n = 76), C. parapsilosis (n = 67), C. glabrata (n = 40), and C. tropicalis (n = 27), respectively. Resistance rate to anidulafungin was high in C. parapsilosis over both periods and increased to 73% in the second period. Fluconazole showed a remarkable decrease for susceptibility in C. parapsilosis (94 to 49%). The prevalence of MDR C. parapsilosis (6%/33%) and C. glabrata (0%/44%) increased in the second period. We observed a predominance of non-albicans Candida spp., with C. parapsilosis being the most frequent and C. glabrata infections presenting with the highest mortality. High level of echinocandin resistance in C. parapsilosis and increasing prevalences of MDR C. parapsilosis and C. glabrata seem emerging challenges in our institution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bassetti M, Peghin M, Timsit JF (2016) The current treatment landscape: candidiasis. J Antimicrob Chemother 71(suppl 2):ii13–ii22

    Article  PubMed  Google Scholar 

  2. Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 373(15):1445–1456

    Article  CAS  PubMed  Google Scholar 

  3. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR et al (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis 55:1352–1361

    Article  CAS  PubMed  Google Scholar 

  4. Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B et al (2015) Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM)(2006–2008). Clin Microbiol Infect 21:87

    Article  PubMed  Google Scholar 

  5. Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, Asia Fungal Working Group (AFWG) et al (2015) Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. Clin Microbiol Infect 21(10):946–953

    Article  CAS  PubMed  Google Scholar 

  6. Eggiman P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702

    Article  Google Scholar 

  7. Sellami A, Sellami H, Neji S, Makni F, Abbes S, Cheikhrouhou F et al (2011) Antifungal susceptibility of bloodstream Candida isolates in Sfax Hospital: Tunisia. Mycopathologia 171(6):417–422

    Article  CAS  PubMed  Google Scholar 

  8. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):e1–e50

    Article  PubMed  Google Scholar 

  9. Schelenz S (2008) Management of candidiasis in the intensive care unit. J Antimicrob Chemother 61(Suppl 1):i31–i34

    Article  CAS  PubMed  Google Scholar 

  10. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ et al (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48:1695–1703

    Article  CAS  PubMed  Google Scholar 

  11. Wan Ismail WNA, Jasmi N, Khan TM, Hong YH, Neoh CF (2019) The economic burden of candidemia and invasive candidiasis: a systematic review. Value Health Reg Issues 21:53–58

    Article  PubMed  Google Scholar 

  12. Pfaller MA, Diekema DJ (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36:1–53

    Article  PubMed  Google Scholar 

  13. Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL (2010) Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 51:561–570

    Article  PubMed  Google Scholar 

  14. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K et al (2012) In vitro susceptibilities of yeast species to fluconazole and voriconazole as determinedby the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol 50:3952–3959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN (2019) Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis 6(Suppl 1):S79–S94

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I (2007) The changing epidemiology of invasive candidiasis. Cancer 112:2334–2337

    Google Scholar 

  17. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR et al (1996) The changing face of candidemia : emergence of non C. albicans species and antifungal resistance. Am J Med 100:617–623

    Article  CAS  PubMed  Google Scholar 

  18. Kontoyiannis DP, Lewis RE (2002) Antifungal drug resistance of pathogenic fungi. Lancet 359:1135–1144

    Article  CAS  PubMed  Google Scholar 

  19. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, et al, Australian and New Zealand Mycoses Interest Group (2017= changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72:1103–8.

  20. Trouve C, Blot S, Hayette MP, Jonckheere S, Patteet S, Rodriguez-Villalobos H et al (2017) Epidemiology and reporting of candidaemia in Belgium: a multi-Centre study. Eur J Clin Microbiol Infect Dis 36:649–655

    Article  CAS  PubMed  Google Scholar 

  21. Pinhati HM, Casulari LA, Souza AC, Siqueira RA, Damasceno CM, Colombo AL (2016) Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit. BMC Infect Dis 16:433

    Article  PubMed  PubMed Central  Google Scholar 

  22. Alp S, Arikan-Akdagli S, Gulmez D, Ascioglu S, Uzun O, Akova M (2015) Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses 58(8):498–505

    Article  PubMed  Google Scholar 

  23. Yeşilkaya A, Azap Ö, Aydın M, Akçil Ok M (2017) Epidemiology, species distribution, clinical characteristics and mortality of candidemia in a tertiary care university hospital in Turkey, 2007-2014. Mycoses 60(7):433–449

    Article  PubMed  Google Scholar 

  24. Kazak E, Akın H, Ener B, Sığırlı D, Özkan Ö, Gürcüoğlu E et al (2014) An investigation of Candida species isolated from blood cultures during 17 years in a university hospital. Mycoses 57(10):623–629

    Article  CAS  PubMed  Google Scholar 

  25. Arikan-Akdagli S, Gülmez D, Doğan Ö, Çerikçioğlu N, Doluca Dereli M, Birinci A et al (2019) First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J Glob Antimicrobiol Res 18:230–234

    Article  Google Scholar 

  26. Arendrup MC, Patterson TF (2017) Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis 216(3):S445–S451

    Article  CAS  PubMed  Google Scholar 

  27. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, the Global Surveillance Group et al (2010) Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 48:1366–1377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vaezi A, Fakhim H, Khodavaisy S, Alizadeh A, Nazeri M, Soleimani A et al (2017) Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis. J Mycol Med 27(2):146–152

    Article  CAS  PubMed  Google Scholar 

  29. Zhou ZL, Lin CC, Chu WL, Yang YL, Lo HJ, TSARY Hospitals (2016) The distribution and drug susceptibilities of clinical Candida species in TSARY 2014. Diagn Microbiol Infect Dis 86(4):399–404

    Article  CAS  PubMed  Google Scholar 

  30. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M et al (2015) Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41:285–295

    Article  PubMed  Google Scholar 

  31. Govender NP, Patel J, Magobo RE, Naicker S, Wadula J, Whitelaw A, TRAC-South Africa group et al (2016) Emergence of azole-resistant Candida parapsilosis causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. J Antimicrob Chemother 71:1994–2004

    Article  CAS  PubMed  Google Scholar 

  32. Montagna MT, Lovero G, Borghi E, Amato G, Andreoni S, Campion L et al (2014) Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 18(5):661–674

    CAS  PubMed  Google Scholar 

  33. Tukenmez Tigen E, Bilgin H, Perk Gurun H, Dogru A, Ozben B, Cerikcioglu N et al (2017) Risk factors, characteristics, and outcomes of candidemia in an adult intensive care unit in Turkey. Am J Infect Control 45(6):e61–e63

    Article  PubMed  Google Scholar 

  34. Horasan ES, Ersöz G, Göksu M, Otag F, Kurt AO, Karaçorlu S et al (2010) Increase in Candida parapsilosis fungemia in critical care units: a 6-years study. Mycopathologia. 170(4):263–268

    Article  PubMed  Google Scholar 

  35. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ (2008) Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 46:2659–2664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Inf Secur 56:126–129

    Google Scholar 

  38. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M et al (2008) Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 36:2034

    Article  PubMed  Google Scholar 

  39. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D et al (2008) Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 46:1206

    Article  PubMed  Google Scholar 

  40. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II et al (2009) Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 115:4745–4752

    Article  CAS  PubMed  Google Scholar 

  41. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54 /12:1739

    Article  CAS  Google Scholar 

  42. Andes DR, Safdar N, Baddley JW, Playford G, Rebolş AC, Rex JH, Mycoses Study Group et al (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54(8):1110

    Article  CAS  PubMed  Google Scholar 

  43. Spellberg BJ, Filler SG, Edwards JE Jr (2006) Current treatment strategies for disseminated candidiasis. Clin Infect Dis 42:244

    Article  CAS  PubMed  Google Scholar 

  44. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al (2008) In vitro susceptibilities of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156

    Article  CAS  PubMed  Google Scholar 

  45. Hesstvedt L, Gaustad P, Andersen CT, Haarr E, Hannula R, Haukland HH et al (2015) Twenty-two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 21(10):938–945

    Article  CAS  PubMed  Google Scholar 

  46. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. 2012; Clinical and Laboratory Standards Institute

  47. Israel S, Amit S, Israel A, Livneh A, Nir-Paz R, Korem M (2019) The epidemiology and susceptibility of candidemia in Jerusalem, Israel. Front Cell Infect Microbiol 9:352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC (2005) Candida orthoplosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 43:284–292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Gonçalves SS, Amorim CS, Nucci M, Padovan AC, Briones MR, Melo AS et al (2010) Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidemia in Brazil. Clin Microbiol Infect 16(7):885–887

    Article  PubMed  Google Scholar 

  50. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, Almirante B, Pahissa A, Rodriguez-Tudela JL, Barcelona Candidemia Project Study Group et al (2008) Barcelona Candidemia project study group prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 52:1506–1509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(6):S612–S617

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Szabó Z, Szilágyi J, Tavanti A, Kardos G, Rozgonyi F, Bayegan S et al (2009) In vitro efficacy of 5 antifungal agents against C. parapsilosis, Candida orthopsilosis and Candida metapsilosis as determined by time-kill methodology. Diagn Microbiol Infect 64:283–288

    Article  CAS  Google Scholar 

  53. Borghi E, Sciota R, Iatta R, Biassoni C, Montagna MT, Morace G (2011) Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis 30(11):1437–1441

    Article  CAS  PubMed  Google Scholar 

  54. Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR et al (2007) Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 45(3):698–706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Arikan S (2007) Current status of antifungal susceptibility testing methods. Med Mycol 45:569–587

    Article  CAS  PubMed  Google Scholar 

  56. Metin DY, Hilmioglu Polat S, Samlioglu P, Doganay Oflazoglu B, Inci RI, Tumbay E (2011) Evaluation of antifungal susceptibility testing with microdilution and E test methods of Candida blood isolates. Mycopathologia 172(3):187–199

    Article  CAS  PubMed  Google Scholar 

  57. Morace G, Borghi E, Iatta R, Amato G, Anderoni S, Brigante G et al (2011) Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. BMC Infect Dis 11:130–138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lovero G, Borghi E, Balbino S, Cirasola D, De Giglio O, Perdoni F et al (2016) Molecular identification and echinocandin susceptibility of candida parapsilosis complex bloodstream isolates in Italy, 2007-2014. PLoS One 11(2):e0150218

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bilgul Mete.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mete, B., Zerdali, E.Y., Aygun, G. et al. Change in species distribution and antifungal susceptibility of candidemias in an intensive care unit of a university hospital (10-year experience). Eur J Clin Microbiol Infect Dis 40, 325–333 (2021). https://doi.org/10.1007/s10096-020-03994-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-020-03994-6

Keywords

Navigation